Janssen R&D Ireland has signed a license agreement with PATH for the early development of the HIV-1 medicine rilpivirine in a long-acting injection as potential pre-exposure prophylaxis (PrEP) against HIV infection.   PATH, an international nonprofit organization, has the right to develop rilpivirine long-acting formulation as a potential new way to prevent HIV infection. PATH plans to conduct prophylaxis clinical trials in collaboration with partners including the HIV Prevention Trials Netw...